

Kayentis

Global provider of eCOA and patient-centric solutions

The 6 challenges to succeed in a global eCOA study

kayentis · Friday, July 8th, 2016

Several elements have to be respected in order to succeed in achieving a global eCOA study. Here is a list which summarizes them item by item.

- *Instruments*
- *Device App*
- *Logistics*
- *Support 24/7 multi-lingual*
- *Connectivity*
- *Good understanding of local rules / specificities.*

6 key challenges to succeed in a global eCOA study!

1

INSTRUMENTS

- ✓ Translation / validation
- ✓ Cognitive debriefings
- ✓ Local language management i.e. avoidance of open questions as much as possible

2

DEVICE APP

- ✓ Navigation (left to right, right to left)
- ✓ Flexibility (only the right languages but all the right languages)
- ✓ Robustness of device (protection support is key to avoid damage)
- ✓ Remote control

3

LOGISTICS

- ✓ Customs clearance including some complex countries (i.e. Russia, China, Mercosur countries, Turkey, etc.)
- ✓ Ongoing logistics- Ad hoc resupply
 - Reallocation of devices to another site
 - Remote change of settings
- ✓ Sunshine Act mgt

4

SUPPORT 24/7 MULTI-LINGUAL

- ✓ Site assistance through a call in local language during the Site Initiation Visit
- ✓ Available at all time
- ✓ Multi-lingual
- ✓ Toll free number regardless of the country

5

CONNECTIVITY

- ✓ WW roaming agreements for sites where WiFi cannot be used (unfortunately most of cases)
- ✓ MiFi is an option, but a costly one

6

GOOD UNDERSTANDING OF LOCAL RULES / SPECIFICITIES

- ✓ Some local privacy rules / declarations
- ✓ WiFi norms in Japan require specific certificate for the devices
- ✓ Vietnam has strict local rules
- ✓ Use of Customs broker to enter in some countries (Israel)

As an expert in electronic capture, Kayentis helps improve clinical trials with electronic solutions and services: improved data quality and reliability, increased productivity, compliance and patient engagement. Kayentis manages a range of eCOA solutions (ePRO, eClinRO, eObsRO, ePerfO, eDiary), taking into account key factors, especially the choice of the device and features to reflect the patient needs, the pathology, or the duration of the trial. If you need more information, please [contact us](#).

Guillaume JUGE, CEO – Kayentis

This entry was posted on Friday, July 8th, 2016 at 12:25 pm and is filed under [Optimizing clinical trials](#)

You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.